Nerve growth factor: from the early discoveries to the potential clinical use

Journal of Translational Medicine

Luigi Manni²  Patrizia Bianchi¹  Maria Luisa Rocco¹  Luigi Aloe¹ 

[1] Cellular Biology and Neurobiology Institute, CNR, via del Fosso di Fiorano 64, 00143, Rome, Italy;Institute of Translational Pharmacology, National Research Council (CNR), via Fosso del Cavaliere 100, 00136, Rome, Italy

关键词: Optic glioma;    Hypoxic-ischemic brain injury;    Glaucoma;    Neurotrophic keratitis;    Skin ulcers;    Peripheral neuropathies;    Parkinson’s disease;    Alzheimer’s disease;    Nerve growth factor;   

Others  :  1205890
DOI  :  10.1186/1479-5876-10-239

 received in 2012-07-19, accepted in 2012-11-21,  发布年份 2012

【 摘 要 】

The physiological role of the neurotrophin nerve growth factor (NGF) has been characterized, since its discovery in the 1950s, first in the sensory and autonomic nervous system, then in central nervous, endocrine and immune systems. NGF plays its trophic role both during development and in adulthood, ensuring the maintenance of phenotypic and functional characteristic of several populations of neurons as well as immune cells. From a translational standpoint, the action of NGF on cholinergic neurons of the basal forebrain and on sensory neurons in dorsal root ganglia first gained researcher’s attention, in view of possible clinical use in Alzheimer’s disease patients and in peripheral neuropathies respectively. The translational and clinical research on NGF have, since then, enlarged the spectrum of diseases that could benefit from NGF treatment, at the same time highlighting possible limitations in the use of the neurotrophin as a drug. In this review we give a comprehensive account for almost all of the clinical trials attempted until now by using NGF. A perspective on future development for translational research on NGF is also discussed, in view of recent proposals for innovative delivery strategies and/or for additional pathologies to be treated, such as ocular and skin diseases, gliomas, traumatic brain injuries, vascular and immune diseases.

【 授权许可】

   
2012 Aloe et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ebendal T: Function and evolution in the NGF family and its receptors. J Neurosci Res 1992, 32:461-470.
• [2]Aloe L, Bracci-Laudiero L, Bonini S, Manni L: The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 1997, 52:883-894.
• [3]Hallbook F: Evolution of the vertebrate neurotrophin and Trk receptor gene families. Curr Opin Neurobiol 1999 Oct, 9:616-621.
• [4]Fahnestock M, Yu G, Michalski B, Mathew S, Colquhoun A, Ross GM, Coughlin MD: The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J Neurochem 2004, 89:581-592.
• [5]Fahnestock M, Yu G, Coughlin MD: ProNGF: a neurotrophic or an apoptotic molecule? Prog Brain Res 2004, 146:101-110.
• [6]Huang EJ, Reichardt LF: TRK receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003, 72:609-642. 609–642
• [7]Klesse LJ, Parada LF: Trks: signal transduction and intracellular pathways. Microsc Res Tech 1999, 45:210-216.
• [8]Chao MV, Rajagopal R, Lee FS: Neurotrophin signalling in health and disease. Clin Sci (Lond) 2006, 110:167-173.
• [9]Reichardt LF: Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361:1545-1564.
• [10]Friedman WJ, Greene LA: Neurotrophin signaling via Trks and p75. Exp Cell Res 1999, 253:131-142.
• [11]Schor NF: The p75 neurotrophin receptor in human development and disease. Prog Neurobiol 2005, 77:201-214.
• [12]Miller FD, Kaplan DR: Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 2001, 58:1045-1053.
• [13]Levi-Montalcini R: The nerve growth factor: thirty-five years later. Science 1987, 237:1154-1162.
• [14]Cowan WM: Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor. Annu Rev Neurosci 2001, 24:551-600.
• [15]Rush RA, Chie E, Liu D, Tafreshi A, Zettler C, Zhou XF: Neurotrophic factors are required by mature sympathetic neurons for survival, transmission and connectivity. Clin Exp Pharmacol Physiol 1997, 24:549-555.
• [16]Alleva E, Aloe L, Bigi S: An updated role for nerve growth factor in neurobehavioural regulation of adult vertebrates. Rev Neurosci 1993, 4:41-62.
• [17]Otten U, Schwab M, Gagnon C, Thoenen H: Selective induction of tyrosine hydroxylase and dopamine beta-hydroxylase by nerve growth factor: comparison between adrenal medulla and sympathetic ganglia of adult and newborn rats. Brain Res 1977, 133:291-303.
• [18]Mearow KM, Kril Y: Anti-NGF treatment blocks the upregulation of NGF receptor mRNA expression associated with collateral sprouting of rat dorsal root ganglion neurons. Neurosci Lett 1995, 184:55-58. 55-58
• [19]Verge VM, Richardson PM, Wiesenfeld-Hallin Z, Hokfelt T: Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J Neurosci 1995, 15:2081-2096.
• [20]Mearowa KM, Kril Y: Anti-NGF treatment blocks the upregulation of NGF receptor mRNA expression associated with collateral sprouting of rat dorsal root ganglion neurons. Neurosci Lett 1995, 184:55-58.
• [21]Lindsay RM, Harmar AJ: Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989, 337:362-364.
• [22]McAllister AK: Neurotrophins and neuronal differentiation in the central nervous system. Cell Mol Life Sci 2001, 58:1054-1060.
• [23]Dreyfus CF: Effects of nerve growth factor on cholinergic brain neurons. Trends Pharmacol Sci 1989, 10:145-149.
• [24]Allen SJ, Dawbarn D: Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 2006, 110:175-191.
• [25]Spillantini MG, Aloe L, Alleva E, De Simone R, Goedert M, Levi-Montalcini R: Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression. Proc Natl Acad Sci USA 1989, 86:8555-8559.
• [26]Aloe L, Alleva E, De Simone R: Changes of NGF level in mouse hypothalamus following intermale aggressive behaviour: biological and immunohistochemical evidence. Behav Brain Res 1990, 39:53-61.
• [27]Taglialatela G, Angelucci L, Scaccianoce S, Foreman PJ, Perez-Polo JR: Nerve growth factor modulates the activation of the hypothalamo-pituitary-adrenocortical axis during the stress response. Endocrinology 1991, 129:2212-2218.
• [28]Scaccianoce S, Cigliana G, Nicolai R, Muscolo LA, Porcu A, Navarra D, Perez-Polo JR, Angelucci L: Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor. Neuroendocrinology 1993, 58:202-209.
• [29]Manni L, Di Fausto V, Fiore M, Aloe L: Repeated restraint and nerve growth factor administration in male and female mice: effect on sympathetic and cardiovascular mediators of the stress response. Curr Neurovasc Res 2008, 5:1-12.
• [30]Aloe L: Nerve growth factor and neuroimmune responses: basic and clinical observations. Arch Physiol Biochem 2001, 109:354-356.
• [31]Bonini S, Lambiase A, Bonini S, Levi-Schaffer F, Aloe L: Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. Int Arch Allergy Immunol 1999, 118:159-162.
• [32]Aloe L, Levi-Montalcini R: Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res 1977, 133:358-366.
• [33]Aloe L: The effect of nerve growth factor and its antibody on mast cells in vivo. J Neuroimmunol 1988, 18:1-12.
• [34]Auffray I, Chevalier S, Froger J, Izac B, Vainchenker W, Gascan H, Coulombel L: Nerve growth factor is involved in the supportive effect by bone marrow–derived stromal cells of the factor-dependent human cell line UT-7. Blood 1996, 88:1608-1618.
• [35]Bracci-Laudiero L, Celestino D, Starace G, Antonelli A, Lambiase A, Procoli A, Rumi C, Lai M, Picardi A, Ballatore G, et al.: CD34-positive cells in human umbilical cord blood express nerve growth factor and its specific receptor TrkA. J Neuroimmunol 2003, 136:130-139.
• [36]Cattoretti G, Schiro R, Orazi A, Soligo D, Colombo MP: Bone marrow stroma in humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro. Blood 1993, 81:1726-1738.
• [37]Chevalier S, Praloran V, Smith C, MacGrogan D, Ip NY, Yancopoulos GD, Brachet P, Pouplard A, Gascan H: Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood 1994, 83:1479-1485.
• [38]Bischoff SC, Dahinden CA: Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood 1992, 79:2662-2669.
• [39]Burgi B, Otten UH, Ochensberger B, Rihs S, Heese K, Ehrhard PB, Ibanez CF, Dahinden CA: Basophil priming by neurotrophic factors. Activation through the trk receptor. J Immunol 1996, 157:5582-5588.
• [40]Gibbs BF, Zillikens D, Grabbe J: Nerve growth factor influences IgE-mediated human basophil activation: functional properties and intracellular mechanisms compared with IL-3. Int Immunopharmacol 2005, 5:735-747.
• [41]Sin AZ, Roche EM, Togias A, Lichtenstein LM, Schroeder JT: Nerve growth factor or IL-3 induces more IL-13 production from basophils of allergic subjects than from basophils of nonallergic subjects. J Allergy Clin Immunol 2001, 108:387-393.
• [42]Takafuji S, Bischoff SC, De Weck AL, Dahinden CA: Opposing effects of tumor necrosis factor-alpha and nerve growth factor upon leukotriene C4 production by human eosinophils triggered with N-formyl-methionyl-leucyl-phenylalanine. Eur J Immunol 1992, 22:969-974.
• [43]Beigelman A, Levy J, Hadad N, Pinsk V, Haim A, Fruchtman Y, Levy R: Abnormal neutrophil chemotactic activity in children with congenital insensitivity to pain with anhidrosis (CIPA): the role of nerve growth factor. Clin Immunol 2009, 130:365-372.
• [44]Boyle MD, Lawman MJ, Gee AP, Young M: Nerve growth factor: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol 1985, 134:564-568.
• [45]Gee AP, Boyle MD, Munger KL, Lawman MJ, Young M: Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci USA 1983, 80:7215-7218.
• [46]Kannan Y, Ushio H, Koyama H, Okada M, Oikawa M, Yoshihara T, Kaneko M, Matsuda H: 2.5S nerve growth factor enhances survival, phagocytosis, and superoxide production of murine neutrophils. Blood 1991, 77:1320-1325.
• [47]Bracci-Laudiero L, Aloe L, Caroleo MC, Buanne P, Costa N, Starace G, Lundeberg T: Endogenous NGF regulates CGRP expression in human monocytes, and affects HLA-DR and CD86 expression and IL-10 production. Blood 2005, 106:3507-3514.
• [48]Brodie C, Gelfand EW: Functional nerve growth factor receptors on human B lymphocytes. Interaction with IL-2. J Immunol 1992, 148:3492-3497.
• [49]Melamed I, Kelleher CA, Franklin RA, Brodie C, Hempstead B, Kaplan D, Gelfand EW: Nerve growth factor signal transduction in human B lymphocytes is mediated by gp140trk. Eur J Immunol 1996, 26:1985-1992.
• [50]Otten U, Ehrhard P, Peck R: Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 1989, 86:10059-10063.
• [51]Torcia M, Bracci-Laudiero L, Lucibello M, Nencioni L, Labardi D, Rubartelli A, Cozzolino F, Aloe L, Garaci E: Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 1996, 85:345-356.
• [52]Ehrhard PB, Erb P, Graumann U, Otten U: Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. Proc Natl Acad Sci USA 1993, 90:10984-10988.
• [53]Lambiase A, Bracci-Laudiero L, Bonini S, Bonini S, Starace G, D'Elios MM, De Carli M, Aloe L: Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. J Allergy Clin Immunol 1997, 100:408-414.
• [54]Noga O, Peiser M, Altenahr M, Knieling H, Wanner R, Hanf G, Grosse R, Suttorp N: Differential activation of dendritic cells by nerve growth factor and brain-derived neurotrophic factor. Clin Exp Allergy 2007, 37:1701-1708.
• [55]Caroleo MC, Costa N, Bracci-Laudiero L, Aloe L: Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors. J Neuroimmunol 2001, 113:193-201.
• [56]Ehrhard PB, Ganter U, Stalder A, Bauer J, Otten U: Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA 1993, 90:5423-5427.
• [57]la Sala A, Corinti S, Federici M, Saragovi HU, Girolomoni G: Ligand activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. J Leukoc Biol 2000, 68:104-110.
• [58]Ma W, Dumont Y, Vercauteren F, Quirion R: Lipopolysaccharide induces calcitonin gene-related peptide in the RAW264.7 macrophage cell line. Immunology 2010, 130:399-409.
• [59]Thorpe LW, Stach RW, Hashim GA, Marchetti D, Perez-Polo JR: Receptors for nerve growth factor on rat spleen mononuclear cells. J Neurosci Res 1987, 17:128-134.
• [60]Seidel MF, Herguijuela M, Forkert R, Otten U: Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010, 40:109-126.
• [61]Scuri M, Samsell L, Piedimonte G: The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets 2010, 9:173-180.
• [62]Kawamoto K, Matsuda H: Nerve growth factor and wound healing. Prog Brain Res 2004, 146:369-384.
• [63]Linker R, Gold R, Luhder F: Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol 2009, 29:43-68.
• [64]Yuen EC, Howe CL, Li Y, Holtzman DM, Mobley WC: Nerve growth factor and the neurotrophic factor hypothesis. Brain Dev 1996, 18:362-368.
• [65]Mendell LM: Neurotrophin action on sensory neurons in adults: an extension of the neurotrophic hypothesis. Pain 1999, (Suppl 6):S127-S132.
• [66]Hellweg R, Hartung HD: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990, 26:258-267.
• [67]Hellweg R, Raivich G, Hartung HD, Hock C, Kreutzberg GW: Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 1994, 130:24-30.
• [68]Apfel SC, Kessler JA: Neurotrophic factors in the therapy of peripheral neuropathy. Baillieres Clin Neurol 1995, 4:593-606.
• [69]McMahon SB, Priestley JV: Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. Curr Opin Neurobiol 1995, 5:616-624.
• [70]Anand P: Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci 1996, 351:449-454.
• [71]Riaz SS, Tomlinson DR: Neurotrophic factors in peripheral neuropathies: pharmacological strategies. Prog Neurobiol 1996, 49:125-143.
• [72]Sima AA: New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003, 60:2445-2464.
• [73]Sima AA, Kamiya H: Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann N Y Acad Sci 2006, 1084:235-249.
• [74]Schmidt RE, Modert CW, Yip HK, Johnson EMJ: Retrograde axonal transport of intravenously administered 125I-nerve growth factor in rats with streptozotocin-induced diabetes. Diabetes 1983, 32:654-663.
• [75]Faradji V, Sotelo J: Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990, 81:402-406.
• [76]Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR: Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem 1995, 64:1231-1237.
• [77]Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ: p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36:57-68.
• [78]Nicol GD, Vasko MR: Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks? Mol Interv 2007, 7:26-41.
• [79]Purves T, Middlemas A, Agthong S, Jude EB, Boulton AJ, Fernyhough P, Tomlinson DR: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001, 15:2508-2514.
• [80]Diemel LT, Brewster WJ, Fernyhough P, Tomlinson DR: Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Brain Res Mol Brain Res 1994, 21:171-175.
• [81]Sango K, Verdes JM, Hikawa N, Horie H, Tanaka S, Inoue S, Sotelo JR, Takenaka T: Nerve growth factor (NGF) restores depletions of calcitonin gene-related peptide and substance P in sensory neurons from diabetic mice in vitro. J Neurol Sci 1994, 126:1-5.
• [82]Apfel SC: Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med 1999, 107:34S-42S.
• [83]Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994, 634:7-12.
• [84]Rogers BC: Development of recombinant human nerve growth factor (rhNGF) as a treatment for peripheral neuropathic disease. Neurotoxicology 1996, 17:865-870.
• [85]Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, Sinicropi D, Burton LE, Peroutka SJ: The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994, 36:244-246.
• [86]Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF study group. Neurology 1998, 51:695-702.
• [87]Apfel SC: Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002, 50:393-413.
• [88]Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF clinical investigator group. JAMA 2000, 284:2215-2221.
• [89]Berger JR, Nath A: Remedies for HIV-associated peripheral neuropathy. Neurology 2000, 54:2037-2038.
• [90]Peltier AC, Russell JW: Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002, 15:633-638.
• [91]Simpson DM, Haidich AB, Schifitto G, Yiannoutsos CT, Geraci AP, McArthur JC, Katzenstein DA: Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002, 16:407-412.
• [92]A phase II, double-blind trial of recombinant human nerve growth factor for treatment of hiv-associated sensory neuropathy [http://clinicaltrials.gov/ct2/show/study/NCT00000842] webcite
• [93]McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, et al.: A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291 [see comments] [published erratum appears in Neurology 2000 Jul 13;55(1):162]. Neurology 2000, 54:1080-1088.
• [94]Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, et al.: Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001, 57:1313-1316.
• [95]Alberts DS, Noel JK: Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs 1995, 6:369-383.
• [96]Konings PN, Makkink WK, van Delft AM, Ruigt GS: Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res 1994, 640:195-204.
• [97]Apfel SC, Arezzo JC, Lipson L, Kessler JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992, 31:76-80.
• [98]Hayakawa K, Sobue G, Itoh T, Mitsuma T: Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci 1994, 55:519-525.
• [99]Schmidt Y, Unger JW, Bartke I, Reiter R: Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol 1995, 132:16-23.
• [100]Hayakawa K, Itoh T, Niwa H, Mutoh T, Sobue G: NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res 1998, 794:313-319.
• [101]Aloe L, Manni L, Properzi F, De Santis S, Fiore M: Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci 2000, 86:84-93.
• [102]Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Franchi D, La Presa MT, Lissoni A, Buda A, et al.: Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004, 15:1439-1442.
• [103]Facer P, Mann D, Mathur R, Pandya S, Ladiwala U, Singhal B, Hongo J, Sinicropi DV, Terenghi G, Anand P: Do nerve growth factor-related mechanisms contribute to loss of cutaneous nociception in leprosy? Pain 2000, 85:231-238.
• [104]Anand P, Pandya S, Ladiwala U, Singhal B, Sinicropi DV, Williams-Chestnut RE: Depletion of nerve growth factor in leprosy. Lancet 1994, 344:129-130.
• [105]Facer P, Mathur R, Pandya SS, Ladiwala U, Singhal BS, Anand P: Correlation of quantitative tests of nerve and target organ dysfunction with skin immunohistology in leprosy. Brain 1998, 121(Pt 12):2239-2247.
• [106]Anand P: Nerve growth factor regulates nociception in human health and disease. Br J Anaesth 1995, 75:201-208.
• [107]Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH: Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987, 329:65-68.
• [108]Hefti F: Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986, 6:2155-2162.
• [109]Kromer LF: Nerve growth factor treatment after brain injury prevents neuronal death. Science 1987, 235:214-216.
• [110]Tuszynski MH, U HS, Amaral DG, Gage FH: Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 1990, 10:3604-3614.
• [111]Tuszynski MH, Sang H, Yoshida K, Gage FH: Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991, 30:625-636.
• [112]Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V: p75 and TrkA receptor signaling independently regulate amyloid precursor protein mRNA expression, isoform composition, and protein secretion in PC12 cells. J Neurochem 1998, 71:757-766.
• [113]Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V: The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol 1998, 56:541-569.
• [114]Tian L, Guo R, Yue X, Lv Q, Ye X, Wang Z, Chen Z, Wu B, Xu G, Liu X: Intranasal administration of nerve growth factor ameliorate beta-amyloid deposition after traumatic brain injury in rats. Brain Res 2012, 1440:47-55.
• [115]Nuydens R, Dispersyn G, de Jong M, van den Kieboom G, Borgers M, Geerts H: Aberrant tau phosphorylation and neurite retraction during NGF deprivation in PC12 cells. Biochem Biophys Res Commun 1997, 240:687-691.
• [116]Zhang ZH, Xi GM, Li WC, Ling HY, Qu P, Fang XB: Cyclic-AMP response element binding protein and tau are involved in the neuroprotective mechanisms of nerve growth factor during focal cerebral ischemia/reperfusion in rats. J Clin Neurosci 2010, 17:353-356.
• [117]Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA: Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995, 15:6213-6221.
• [118]Pan W, Banks WA, Kastin AJ: Permeability of the blood–brain barrier to neurotrophins. Brain Res 1998, 788:87-94.
• [119]Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A, et al.: Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 1992, 4:79-95.
• [120]Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger , Shigeta M, Theodorsson E, et al.: Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998, 9:246-257.
• [121]Olson L, Backlund EO, Ebendal T, Freedman R, Hamberger B, Hansson P, Hoffer B, Lindblom U, Meyerson B, Stromberg I, et al.: Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson’s disease. One-year follow-up of first clinical trial. Arch Neurol 1991, 48:373-381.
• [122]Chiaretti A, Antonelli A, Genovese O, Fernandez E, Giuda D, Mariotti P, Riccardi R: Intraventricular nerve growth factor infusion improves cerebral blood flow and stimulates doublecortin expression in two infants with hypoxic-ischemic brain injury. Neurol Res 2008, 30:223-228.
• [123]Chiaretti A, Genovese O, Riccardi R, Di Rocco C, Di Giuda D, Mariotti P, Pulitano S, Piastra M, Polidori G, Colafati GS, Aloe L: Intraventricular nerve growth factor infusion: a possible treatment for neurological deficits following hypoxic-ischemic brain injury in infants. Neurol Res 2005, 27:741-746.
• [124]Chiaretti A, Piastra M, Polidori G, Di Rocco C, Caresta E, Antonelli A, Amendola T, Aloe L: Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury. Intensive Care Med 2003, 29:1329-1338.
• [125]Date I, Ohmoto T: Neural transplantation and trophic factors in Parkinson's disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine-secreting cell grafting. Exp Neurol 1996, 137:333-344.
• [126]Olson L, Backman L, Ebendal T, Eriksdotter-Jonhagen M, Hoffer B, Humpel C, Freedman R, Giacobini M, Meyerson B, Nordberg A, et al.: Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. J Neurol 1994, 242:S12-S15.
• [127]Lindvall O, Backlund EO, Farde L, Sedvall G, Freedman R, Hoffer B, Nobin A, Seiger A, Olson L: Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol 1987, 22:457-468.
• [128]Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Seiger A, Olson L: Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985, 62:169-173.
• [129]Herrera-Marschitz M, Stromberg I, Olsson D, Ungerstedt U, Olson L: Adrenal medullary implants in the dopamine-denervated rat striatum. II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics. Brain Res 1984, 297:53-61.
• [130]Stromberg I, Herrera-Marschitz M, Hultgren L, Ungerstedt U, Olson L: Adrenal medullary implants in the dopamine-denervated rat striatum. I. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis. Brain Res 1984, 297:41-51.
• [131]Holtzman DM, Sheldon RA, Jaffe W, Cheng Y, Ferriero DM: Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 1996, 39:114-122.
• [132]Di Marco E, Marchisio PC, Bondanza S, Franzi AT, Cancedda R, De Luca M: Growth-regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes. J Biol Chem 1991, 266:21718-21722.
• [133]Pincelli C, Sevignani C, Manfredini R, Grande A, Fantini F, Bracci-Laudiero L, Aloe L, Ferrari S, Cossarizza A, Giannetti A: Expression and function of nerve growth factor and nerve growth factor receptor on cultured keratinocytes. J Invest Dermatol 1994, 103:13-18.
• [134]Pincelli C, Marconi A: Autocrine nerve growth factor in human keratinocytes. J Dermatol Sci 2000, 22:71-79.
• [135]Tuveri MA, Passiu G, Mathieu A, Aloe L: Nerve growth factor and mast cell distribution in the skin of patients with systemic sclerosis. Clin Exp Rheumatol 1993, 11:319-322.
• [136]Woolf CJ, Ma QP, Allchorne A, Poole S: Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation. J Neurosci 1996, 16:2716-2723.
• [137]Bull HA, Leslie TA, Chopra S, Dowd PM: Expression of nerve growth factor receptors in cutaneous inflammation. Br J Dermatol 1998, 139:776-783.
• [138]Antunes SL, Sarno EN, Holmkvist G, Johansson O: A comparison of the expression of NGFr, PGP 9.5 and NSE in cutaneous lesions of patients with early leprosy using immunohistochemistry. Int J Lepr Other Mycobact Dis 1997, 65:357-365.
• [139]Terenghi G, Mann D, Kopelman PG, Anand P: trkA and trkC expression is increased in human diabetic skin. Neurosci Lett 1997, 228:33-36.
• [140]Matsuda H, Koyama H, Sato H, Sawada J, Itakura A, Tanaka A, Matsumoto M, Konno K, Ushio H, Matsuda K: Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med 1998, 187:297-306.
• [141]Raychaudhuri SP, Jiang WY, Farber EM: Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol 1998, 78:84-86.
• [142]Artuc M, Hermes B, Steckelings UM, Grutzkau A, Henz BM: Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol 1999, 8:1-16.
• [143]Sivilia S, Paradisi M, D'Intino G, Fernandez M, Pirondi S, Lorenzini L, Calza L: Skin homeostasis during inflammation: a role for nerve growth factor. Histol Histopathol 2008, 23:1-10.
• [144]Chen WP, Chang YC, Hsieh ST: Trophic interactions between sensory nerves and their targets. J Biomed Sci 1999, 6:79-85.
• [145]Raud J, Lundeberg T, Brodda-Jansen G, Theodorsson E, Hedqvist P: Potent anti-inflammatory action of calcitonin gene-related peptide. Biochem Biophys Res Commun 1991, 180:1429-1435.
• [146]Newbold P, Brain SD: The modulation of inflammatory oedema by calcitonin gene-related peptide. Br J Pharmacol 1993, 108:705-710. 705-710
• [147]Kahler CM, Sitte BA, Reinisch N, Wiedermann CJ: Stimulation of the chemotactic migration of human fibroblasts by substance P. Eur J Pharmacol 1993 Nov 16, 249:281-286.
• [148]Amann R, Egger T, Schuligoi R: The tachykinin NK(1) receptor antagonist SR140333 prevents the increase of nerve growth factor in rat paw skin induced by substance P or neurogenic inflammation. Neuroscience 2000, 100:611-615. 611-615
• [149]Burbach GJ, Kim KH, Zivony AS, Kim A, Aranda J, Wright S, Naik SM, Caughman SW, Ansel JC, Armstrong CA: The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol 2001, 117:1075-1082.
• [150]Amann R, Schuligoi R: Beta adrenergic inhibition of capsaicin-induced, NK1 receptor-mediated nerve growth factor biosynthesis in rat skin. Pain 2004, 112:76-82.
• [151]Galkowska H, Olszewski WL, Wojewodzka U, Rosinski G, Karnafel W: Neurogenic factors in the impaired healing of diabetic foot ulcers. J Surg Res 2006, 134:252-258.
• [152]Peters EM, Raap U, Welker P, Tanaka A, Matsuda H, Pavlovic-Masnicosa S, Hendrix S, Pincelli C: Neurotrophins act as neuroendocrine regulators of skin homeostasis in health and disease. Horm Metab Res 2007, 39:110-124.
• [153]Li AK, Koroly MJ, Schattenkerk ME, Malt RA, Young M: Nerve growth factor: acceleration of the rate of wound healing in mice. Proc Natl Acad Sci USA 1980, 77:4379-4381.
• [154]Generini S, Tuveri MA, Matucci Cerinic M, Mastinu F, Manni L, Aloe L: Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes 2004, 112:542-544.
• [155]Tuveri M, Generini S, Matucci-Cerinic M, Aloe L: NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet 2000, 356:1739-1740.
• [156]Bernabei R, Landi F, Bonini S, Onder G, Lambiase A, Pola R, Aloe L: Effect of topical application of nerve-growth factor on pressure ulcers. Lancet 1999, 354:307.
• [157]Landi F, Aloe L, Russo A, Cesari M, Onder G, Bonini S, Carbonin PU, Bernabei R: Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med 2003, 139:635-641.
• [158]Chiaretti A, Piastra M, Caresta E, Nanni L, Aloe L: Improving ischaemic skin revascularisation by nerve growth factor in a child with crush syndrome. Arch Dis Child 2002, 87:446-448.
• [159]Calza L, Giardino L, Giuliani A, Aloe L, Levi-Montalcini R: Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Natl Acad Sci USA 2001, 98:4160-4165.
• [160]Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X: Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer 2010, 9:157.
• [161]Tapia V, Gabler F, Munoz M, Yazigi R, Paredes A, Selman A, Vega M, Romero C: Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer. Gynecol Oncol 2011, 121:13-23.
• [162]Lazarovici P, Marcinkiewicz C, Lelkes PI: Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr Pharm Des 2006, 12:2609-2622.
• [163]Campos X, Munoz Y, Selman A, Yazigi R, Moyano L, Weinstein-Oppenheimer C, Lara HE, Romero C: Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer. Gynecol Oncol 2007, 104:168-175.
• [164]Turner JE, Delaney RK: Retinal ganglion cell response to axotomy and nerve growth factor in the regenerating visual system of the newt (Notophthalmus viridescens): an ultrastructural morphometric analysis. Brain Res 1979, 171:197-212.
• [165]Yip HK, Johnson EM Jr: Retrograde transport of nerve growth factor in lesioned goldfish retinal ganglion cells. J Neurosci 1983, 3:2172-2182.
• [166]Carmignoto G, Canella R, Candeo P, Comelli MC, Maffei L: Effects of nerve growth factor on neuronal plasticity of the kitten visual cortex. J Physiol 1993, 464:343-360.
• [167]Carmignoto G, Maffei L, Candeo P, Canella R, Comelli C: Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J Neurosci 1989, 9:1263-1272.
• [168]Lambiase A, Aloe L: Nerve growth factor delays retinal degeneration in C3H mice. Graefes Arch Clin Exp Ophthalmol 1996, 234(Suppl 1):S96-S100.
• [169]Lenzi L, Coassin M, Lambiase A, Bonini S, Amendola T, Aloe L: Effect of exogenous administration of nerve growth factor in the retina of rats with inherited retinitis pigmentosa. Vision Res 2005, 45:1491-1500.
• [170]Lambiase A, Centofanti M, Micera A, Manni GL, Mattei E, De Gregorio A, de Feo G, Bucci MG, Aloe L: Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol 1997, 235:780-785.
• [171]Lambiase A, Bonini S, Micera A, Rama P, Bonini S, Aloe L: Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci 1998, 39:1272-1275.
• [172]Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L: Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 1998, 338:1174-1180.
• [173]de Castro F, Silos-Santiago I, Lopez de Armentia M, Barbacid M, Belmonte C: Corneal innervation and sensitivity to noxious stimuli in trkA knockout mice. Eur J Neurosci 1998, 10:146-152.
• [174]Ebendal T, Persson H: Detection of nerve growth factor mRNA in the developing chicken embryo. Development 1988, 102:101-106.
• [175]Terenghi G, Zhang SQ, Unger WG, Polak JM: Morphological changes of sensory CGRP-immunoreactive and sympathetic nerves in peripheral tissues following chronic denervation. Histochemistry 1986, 86:89-95.
• [176]Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L: Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 2000, 107:1347-1351. discussion 1351–1342
• [177]Lambiase A, Coassin M, Sposato V, Micera A, Sacchetti M, Bonini S, Aloe L: NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. Pharmacol Res 2007, 56:65-69.
• [178]Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V, Manni GL, Bucci MG, Bonini S, Levi-Montalcini R: Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci USA 2009, 106:13469-13474.
• [179]Lambiase A, Coassin M, Tirassa P, Mantelli F, Aloe L: Nerve growth factor eye drops improve visual acuity and electrofunctional activity in age-related macular degeneration: a case report. Ann Ist Super Sanita 2009, 45:439-442.
• [180]Blesch A, Tuszynski M: Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Clin Neurosci 1995, 3:268-274.
• [181]Tuszynski MH, Roberts J, Senut MC, U HS, Gage FH: Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther 1996, 3:305-314.
• [182]Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, et al.: A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11:551-555.
• [183]Mandel RJ: CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 2010, 12:240-247.
• [184][http://clinicaltrials.gov/ct2/show/NCT00087789] webciteCERE-110 in Subjects With Mild to Moderate Alzheimer's Disease.
• [185][http://clinicaltrials.gov/ct2/show/NCT00876863] webciteRandomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease.
• [186][http://clinicaltrials.gov/ct2/show/NCT01163825] webciteEncapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer′s Disease Patients (NsG0202).
• [187]Wahlberg LU, Lind G, Almqvist PM, Kusk P, Tornoe J, Juliusson B, Soderman M, Sellden E, Seiger A, Eriksdotter-Jonhagen M, Linderoth B: Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg 2012, 117:340-347.
• [188]Hoffman D, Breakefield XO, Short MP, Aebischer P: Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp Neurol 1993, 122:100-106.
• [189]Hoffman D, Wahlberg L, Aebischer P: NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Exp Neurol 1990, 110:39-44.
• [190]Eriksdotter-Jonhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N, Blennow K, Bogdanovic N, Jelic V, Kadir A, et al.: Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012, 33:18-28.
• [191]Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T: Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012, 97:366-376.
• [192]Guastella AJ, MacLeod C: A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm Behav 2012, 61:410-418.
• [193]Rilling JK, DeMarco AC, Hackett PD, Thompson R, Ditzen B, Patel R, Pagnoni G: Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men. Psychoneuroendocrinology 2012, 37:447-461.
• [194]Mathison S, Nagilla R, Kompella UB: Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 1998, 5:415-441.
• [195]Liu XF, Fawcett JR, Thorne RG, Frey WH 2nd: Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 2001, 308:91-94.
• [196]Illum L: Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004, 56:3-17.
• [197]Cattaneo A, Capsoni S, Paoletti F: Towards non invasive nerve growth factor therapies for Alzheimer's disease. J Alzheimers Dis 2008, 15:255-283.
• [198]Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A: Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res 2009, 6:158-170.
• [199]Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G, Malerba F, Paoletti F, Meli G, Viegi A, Pavone F, Cattaneo A: Intranasal "painless" human Nerve Growth Factors slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice. PLoS One 2012, 7:e37555.
• [200]Capsoni S, Covaceuszach S, Marinelli S, Ceci M, Bernardo A, Minghetti L, Ugolini G, Pavone F, Cattaneo A: Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PLoS One 2011, 6:e17321.
• [201]Lambiase A, Pagani L, Di Fausto V, Sposato V, Coassin M, Bonini S, Aloe L: Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: biochemical and structural evidence. Brain Res 2007, 1127:45-51.
• [202]Calza A, Florenzano F, Pellegrini D, Tirassa P: Time-dependent activation of c-fos in limbic brain areas by ocular administration of nerve growth factor in adult rats. J Ocul Pharmacol Ther 2011, 27:209-218.
• [203]Tirassa P: The nerve growth factor administrated as eye drops activates mature and precursor cells in subventricular zone of adult rats. Arch Ital Biol 2011, 149:205-213.
• [204]Dhuria SV, Hanson LR, Frey WH 2nd: Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010, 99:1654-1673.
• [205]Capsoni S, Covaceuszach S, Ugolini G, Spirito F, Vignone D, Stefanini B, Amato G, Cattaneo A: Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice. J Alzheimers Dis 2009, 16:371-388.
• [206]Falsini B, Chiaretti A, Barone G, Piccardi M, Pierri F, Colosimo C, Lazzareschi I, Ruggiero A, Parisi V, Fadda A, et al.: Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: a pilot study including electrophysiology. Neurorehabil Neural Repair 2011, 25:512-520.
• [207]Chiaretti A, Falsini B, Servidei S, Marangoni D, Pierri F, Riccardi R: Nerve growth factor eye drop administration improves visual function in a patient with optic glioma. Neurorehabil Neural Repair 2011, 25:386-390.